Buccal Mucoadhesive Tablets of Sumatriptan Succinate for Treatment of Sustainable Migraine: Design, Formulation and In Vitro Evaluation

The objective of present studies were to develop a Sumatriptan succinate buccal mucoadhesive tablet using mucoadhesive polymers such as HPMC K4M, Carbopol 934P, ethyl cellulose and guar gum in alone and in combination as release retarding agent to prolong the drug release, to increase mucoadhesive strength and to avoid first pass metabolism. The mucoadhesive buccal tablets were prepared by direct compression method. The dry blend of drug and polymers were evaluated for precompression parameters to ensure flow properties during tablet punching. The prepared mucoadhesive buccal tablets were evaluated for physicochemical parameters such as hardness, thickness uniformity, weight variation, and moisture absorption studies. The prepared buccal tablets were also evaluated for mucoadhesive strength, in vitro drug release and ex vivo drug permeation through goat buccal mucosa. The drug excipients compatibility was evaluated by FTIR and DSC studies. Ex vivo mucoadhesive strength, and in vitro release studies showed that formulation SMF12 containing 12.5% of each polymer combination showed satisfactory bioadhesive strength and exhibited optimum drug release (99.33 % after 10hrs). FTIR and DSC results showed no evidence of interaction between the Sumatriptan succinate and mucoadhesive polymers. The Stability of Sumatriptan mucoadhesive buccal tablets was determined in artificial human saliva and it was found that both Sumatriptan succinate and buccal tablets were stable in human saliva. Hence different mucoadhesive polymers (HPMC K4M, Carbopol 934P, ethyl cellulose and guar gum) in various proportions can be used to prepare mucoadhesive buccal tablets of Sumatriptan succinate having prolonged therapeutic effect with enhanced patience compliance by avoiding first pass metabolism.